Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vedere Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"$150.0 million","newsHeadline":"Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Octagon Capital","pharmaFlowCategory":"D","amount":"$77.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vedere Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform at the 25th Annual ASGCT Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Vedere Bio

    Menu

    Vedere Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vedere Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform at the 25th Annual ASGCT Meeting

              Details:

              Vedere successfully developed a suspension cell line (X-RAP™), which along with demonstrating zero cell aggregation in high density cultures, consumes less nutrients, quintuples the percent-full capsids and has a titer ~1.8x greater than a commercially available cell line.

              Lead Product(s): AAV Based Capsid

              Therapeutic Area: Ophthalmology Product Name: rAAV

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vedere Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vedere Bio II to Present Two Abstracts at the ASGCT 2022 Annual Meeting

              Details:

              The presentations will showcase four novel, proprietary AAV Based Gene Therapy, with high retinal transduction efficiency, as well as a new cell line (X-RAP™) for rAAV manufacturing.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vedere Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies

              Details:

              Vedere Bio II is a privately held, emerging biopharmaceutical company leveraging mutation agnostic technology and novel AAV capsids to restore vision in all patients with vision loss due to photoreceptor cell death.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Octagon Capital

              Deal Size: $77.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing May 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vedere Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

              Details:

              Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss.

              Lead Product(s): AAV-based Gene Therapy

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: $280.0 million Upfront Cash: $150.0 million

              Deal Type: Acquisition October 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY